DGAP-News: Second Trial Data Report: Clinical Substantiation for CVR Medical

Nachricht vom 07.03.2018 (www.4investors.de) -

DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous

Second Trial Data Report: Clinical Substantiation for CVR Medical
07.03.2018 / 14:30

The issuer is solely responsible for the content of this announcement.

Vancouver, British Columbia--(Newsfile Corp. - March 7, 2018) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') advisory staff member Dr. Phillip J. Bendick, PhD, has completed his second clinical report summarizing additional data collected from tertiary clinical trials for the Carotid Stenotic Scan (CSS) device. His report confirms the evaluation stated in the prior report, issued in September 2017, which predicted improved accuracy in the ability to identify the narrowing of arteries. In commenting on the report, evaluating 295 Carotid Arteries within tertiary clinical trials, Dr. Bendick states, 'Internal re-evaluation of the tertiary clinical data for the Carotid Stenotic Scan (CSS) using the latest software has shown significant improvement in the ability to accurately differentiate carotid arteries without stenosis versus those with clinically important atherosclerotic disease.'Dr. Bendick elaborates, 'In the current device, we were able to continue to improve the quality of placement metric through the enhanced user interface, significantly refining the CSS's level of accuracy. Within the upper and lower ranges of acceptable data as defined by the improved software, the CSS concurred with Duplex Doppler Ultrasound 235 times out of 295 total tests (lower threshold) and 255 times out of 263 (upper threshold).' Dr. Bendick goes on to explain, 'The CSS is currently in pivotal clinical trials as of March 5, 2018. The data collected in these trials align with our plans for expansion of a patient database, increasing the number of carotid arteries with clinically important narrowing, providing data for rigorous testing of the software's accuracy and efficacy.'Data from current pivotal trials at all locations will be used for clinical substantiation of CVR's upcoming FDA submission. For additional information on the organization, leadership, and current news, please visit the company website www.CVRMed.com.About CVR MedicalCVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.On behalf of the Board:(signed) 'Peter Bakema'CEO, President & DirectorFor further information contact:Peter Bakema, CEO, President and DirectorTelephone: (734) 718-5115Email: info@cvrmed.comorBrisco Capital Partners Corp.Scott Koyich, PresidentTelephone: (403) 262-9888This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Click on, or paste the following link into your web browser, to view
the associated documents


07.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

CVR Medical Corp.


End of News
DGAP News Service

661443  07.03.2018 

PfeilbuttonOhne Depotgebühren. Mit Kosten-Airbag. Das Wertpapierdepot der MERKUR BANK.

4investors Exklusiv-Berichte und Interviews:
PfeilbuttonR-LOGITECH: „Akquisitionen liegen in unserer DNA“
PfeilbuttonMagForce: NanoTherm soll ein weltweiter Erfolg werden
PfeilbuttonCLIQ Digital AG: „Playfilms ist eine echte Erfolgsgeschichte“

Aktuelle Nachrichten aus der 4investors-Redaktion

23.03.2018 - DWS: Kein faszinierender Start
23.03.2018 - InterCard: Ergebnis gibt deutlich nach
23.03.2018 - ElringKlinger: Elektromobilität rückt in den Fokus
23.03.2018 - Indus: Vorstandschef geht
23.03.2018 - Baader Bank: Zurück in der Gewinnzone
23.03.2018 - Vectron verzeichnet Gewinneinbruch
23.03.2018 - Hamborner REIT holt sich 75 Millionen Euro
23.03.2018 - Deutsche Wohnen hebt die Dividende an
23.03.2018 - Siemens Healthineers Aktie: Spannung nach Gewinnmitnahmen - nächster Schub nach oben?
23.03.2018 - Aixtron Aktie: Vorsicht, Gefahr!


23.03.2018 - Siemens Healthineers Aktie: Spannung nach Gewinnmitnahmen - nächster Schub nach oben?
23.03.2018 - Aixtron Aktie: Vorsicht, Gefahr!
23.03.2018 - Steinhoff Aktie: Kein Ende der Talfahrt
23.03.2018 - Geely Aktie mit Intraday-Wende: Hoffnung kommt auf!
23.03.2018 - Deutsche Bank Aktie: Vorsicht, hier könnte der nächste Sturz anstehen!
23.03.2018 - Commerzbank Aktie: Der nächste Schock?
23.03.2018 - Medigene Aktie: Richtig schlechte News
22.03.2018 - 1+1 Drillisch Aktie: Ist der Selloff beendet?
22.03.2018 - Commerzbank und Deutsche Bank: Üble Sache, aber…
22.03.2018 - Commerzbank Aktie: Droht hier wegen der Deutschen Bank Schlimmeres?


23.03.2018 - RIB Software: Ein schwerer Rückschlag
23.03.2018 - Wirecard: Indien beeindruckt
23.03.2018 - 1+1 Drillisch: Wieder im Aufwärtsmodus - Kaufempfehlung
23.03.2018 - Cancom: Kaufempfehlung entfällt
23.03.2018 - RWE: Kaum Bewegung beim Kurs
23.03.2018 - Medigene: Weiteres Abwärtspotenzial
23.03.2018 - Grammer: Fragen und Unsicherheiten
23.03.2018 - RIB Software: Deutliche Kritik
23.03.2018 - Deutsche Bank: Zweischneidiger Börsengang
23.03.2018 - Paion: Kursziel sinkt nach den Zahlen


23.03.2018 - Verliert Deutschland als Handelsmacht an Bedeutung? - CMC Markets Kolumne
23.03.2018 - DAX: Die Angst vor einem Handelskrieg drückt den DAX unter 12.000 Punkte - Nord LB Kolumne
23.03.2018 - Unternehmensstimmung im Euroraum trübt sich weiter ein - Commerzbank Kolumne
23.03.2018 - DAX: Handelskrieg belastet - Donner + Reuschel Kolumne
23.03.2018 - Volkswagen Aktie: Kurzfristig weiteres Abwärtspotenzial vorhanden - UBS Kolumne
23.03.2018 - DAX: Erneuter Test der 12.000-Punkte-Marke - UBS Kolumne
22.03.2018 - Fed erhöht Zinsausblick für 2019 und 2020 - Commerzbank Kolumne
22.03.2018 - Schlechte Konjunkturdaten = fallender DAX? Nicht unbedingt! - Donner + Reuschel Kolumne
22.03.2018 - Siemens Aktie: Weiterer Kursrückgang möglich - UBS Kolumne
22.03.2018 - DAX: Zurückhaltung vor dem FED-Zinsentscheid - UBS Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR